Rapid susceptibility testing of medically important zygomycetes by XTT assay

Journal of Clinical Microbiology

Volumn 44, Issue 2, 2006, Pages 553-560

  Antachopoulos, Charalampos ^a   Meletiadis, Joseph ^a   Roilides, Emmanuel ^a,b   Sein, Tin ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BIS[2 METHOXY 4 NITRO 5 [(SULFENYLAMINO)CARBONYL] 2H TETRAZOLIUM; AMPHOTERICIN B; MENADIONE; POSACONAZOLE; TETRAZOLIUM; UNCLASSIFIED DRUG; VORICONAZOLE;

ABSIDIA; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS; COLORIMETRY; CONTROLLED STUDY; CUNNINGHAMELLA; FUNGAL BIOMASS; FUNGAL METABOLISM; FUNGUS GROWTH; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUCOR; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS ORYZAE; SPECTROPHOTOMETRY; ZYGOMYCETES;

ANTIFUNGAL AGENTS; BIOMASS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUCORALES; MUCORMYCOSIS; TETRAZOLIUM SALTS; TIME FACTORS;

ABSIDIA; ABSIDIA CORYMBIFERA; ASPERGILLUS; CUNNINGHAMELLA; FUNGI; MUCOR; RHIZOPUS ORYZAE; ZYGOMYCETES;

EID: 32344434879     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.44.2.553-560.2006     Document Type: Article

References (22)

1. Ahmed, A. O., W. W. van de Sande, W. van Vianen, A. van Belkum, A. H. Fahal, H. A. Verbrugh, and I. A. Bakker-Woudenberg. 2004. In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-bis (2-methoxy-4-nitro-5-sulfophenyI)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay. Antimicrob. Agents Chemother. 48:2742-2746.
2. Balajee, S. A., A. Irahof, J. L. Gribskov, and K. A. Marr. 2005. Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay. J. Antimicrob. Chemother. 55:102-105.
3. Balajee, S. A., and K. A. Marr. 2002. Conidial viability assay for rapid susceptibility testing of Aspergillus species. J. Clin. Microbiol. 40:2741-2745.
4. Dannaoui, E., J. F. Meis, D. Loebenberg, and P. E. Verweij. 2003. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47:3647-3650.
5. Dannaoui, E., J. Meletiadis, J. W. Mouton, J. F. Meis, and P. E. Verweij. 2003. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51:45-52.
6. Diekema, D. J., S. A. Messer, R. J. Hollis, R. N. Jones, and M. A. Pfaller. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41:3623-3626.
7. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, Jr., A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsh, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
8. Gil-Lamaignere, C., R. Hess, S. Salvenraoser, K. Heyn, R. Kappe, and F. M. Muller. 2005. Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. J. Antimicrob. Chemother. 55:1016-1019.
9. Groll, A. H., J. C. Gea-Banacloche, A. Glasmacher, G. Just-Nuebling, G. Maschmeyer, and T. J. Walsh. 2003. Clinical pharmacology of antifungal compounds. Infect. Dis. Clin. N. Am. 17:159-191, ix.
10. Kontoyiannis, D. P., M. S. Lionakis, R. E. Lewis, G. Chamilos, M. Healy, C. Perego, A. Safdar, H. Kantarjian, R. Champlin, T. J. Walsh, and I.I. Raad. 2005. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191:1350-1360.
11. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, J. P. Donnelly, and P. E. Verweij. 2001. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:3402-3408.
12. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, P. J. Donnelly, and P. E. Verweij. 2001. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide}, for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:4256-4263.
13. Meletiadis, J., D. T. te Dorsthorst, and P. E. Verwey. 2003. Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi. J. Clin. Microbiol. 41:4718-4725.
14. Merz, W. G., D. Fay, B. Thuraar, and D. Dixon. 1984. Susceptibility testing of filamentous fungi to amphotericin B by a rapid radiometric method. J. Clin. Microbiol. 19:54-56.
15. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. NCCLS document M38-A. NCCLS, Wayne, Pa.
16. Pagano, L., M. Offidani, L. Fianchi, A. Nosari, A. Candoni, M. Piccardi, L. Corvatta, D. D'Antonio, C. Girmenia, P. Martino, and A. Del Favero. 2004. Mucormycosis in hematologic patients. Haematologica 89:207-214.
17. Pfaller, M. A., and M. G. Rinaldi. 1993. Antifungal susceptibility testing. Current state of technology, limitations, and standardization. Infect. Dis. Clin. N. Am. 7:435-444.
18. Roden, M. M., T. E. Zaoutis, W. L. Buchanan, T. A. Knudsen, T. A. Sarkisova, R. L. Schaufele, M. Sein, T. Sein, C. C. Chiou, J. H. Chu, D. P. Kontoyiannis, and T. J. Walsh. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653.
19. Spellberg, B., J. Edwards, Jr., and A. Ibrahim. 2005. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18:556-569.
20. Sun, Q. N., A. W. Fothergill, D. I. McCarthy, M. G. Rinaldi, and J. R. Graybill. 2002. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 46:1581-1582.
21. Sun, Q. N., L. K. Najvar, R. Bocanegra, D. Loebenberg, and J. R. Graybill. 2002. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother. 46:2310-2312.
22. Tobon, A. M., M. Arango, D. Fernandez, and A. Restrepo. 2003. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. 36:1488-1491.